Table 1.
Baseline SCLC patient clinical characteristics (n = 20) and lesions (n = 24) treatments.
| n (%) | |
|---|---|
| Median age (years, range) | 67.7 (43.1–76.4) |
| Gender | |
| Male | 12 (60) |
| Female | 8 (40) |
| Initial stage | |
| Limited | 12 (60) |
| Extensive | 8 (40) |
| Prior treatments | |
| Thoracic chemoradiotherapy | 12 (60) |
| PCI | 11 (55) |
| First line doublet-chemotherapy | 8 (40) |
| Chemo-immunotherapy | 1 (5) |
| Palliative thoracic irradiation | 2 (10) |
| WBRT | 5 (25) |
| Subsequent line(s) of chemotherapy | 7 (35) |
| Brain SRS | 1 (5) |
| Local ablative treatments | 1 (5) |
| Type of oligometastatic disease | |
| Oligoprogression | 6 (30) |
| Oligorecurrence | 14 (70) |
| ECOG PS before SBRT | |
| 0 | 4 (20) |
| 1 | 16 (80) |
| SBRT (n = 24 lesions) | |
| Median dose (Gy, range) | 48 (30–60) |
| Median EQD2 (Gy, range) | 83.3 (40–110) |
| Median number of fractions (range) | 5 (3–10) |
| Median duration (days, range) | 9 (3–17) |
| Median lesion size (mm, range) | 26 (7–57) |
| Techniques | |
| Static 3D (4D-CT, free breathing) | 10 (42) |
| Static 3D (DIBH) | 2 (8) |
| VMAT (4D-CT, free breathing) | 7 (29) |
| Tracking CyberKnife® | 5 (21) |
| Locations | |
| Lung | 17 (71) |
| Adrenal | 5 (21) |
| Spine | 1 (4) |
| Pancreas | 1 (4) |
SCLC, Small cell lung cancer; PCI, prophylactic cerebral irradiation; WBRT, whole brain radiation therapy; SBRT, stereotactic body radiation therapy; SRS, stereotactic radiosurgery; EQD2: equivalent dose in 2-Gy fractions; 4D-CT, four-dimension computed-tomography; DIBH, Deep inspiration breath hold.